Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Abstract Text:

BACKGROUND: This Phase IIb study explored the antiviral activity and safety of the investigational CCR5 antagonist aplaviroc (APL) in antiretroviral-naive patients harbouring R5-tropic virus. METHODS: One hundred and forty-seven patients were randomized 2:2:1 to one of two APL dosing regimens or efavirenz (EFV). All dosage arms were administered twice daily and in combination with lamivudine/zidovudine (3TC/ZDV; Combivir, COM). Efficacy, safety, and pharmacokinetic parameters were assessed. RESULTS: This study was prematurely terminated due to APL-associated idiosyncratic hepatotoxicity. The primary endpoint of the study was the proportion of patients with plasma HIV-1 RNA <400 copies/ml who remained on randomized treatment through week 12. Of the 147 patients enrolled, 145 patients received one dose of treatment and were included in the intention-to-treat population. The proportion of patients with HIV-1 RNA <400 copies/ml at week 12 was 53%, 50% and 66% in the APL 600 mg twice daily, APL 800 mg twice daily, and EFV arms, respectively. Common clinical adverse events (AEs) were diarrhoea, nausea, fatigue and headache. APL demonstrated non-linear pharmacokinetics with high interpatient variability. In addition to the hepatic findings, there was an apparent dose-response relationship in the incidence of diarrhoea. CONCLUSIONS: Whereas target plasma concentrations of APL were achieved, the antiviral activity of APL as the third agent in a triple drug regimen did not appear to be comparable to EFV in this treatment-naive patient population.

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Antiviral therapy

VOLUME: 13

Page Numbers: 297-306

Journal Abbreviation: Antivir. Ther. (Lond.)

ISSN: 1359-6535

DAY: 28

MONTH: 05

YEAR: 2008

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9815705

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.

AFFILIATION: UCLA Center for Care, Los Angeles, CA, United States. JSCurrier@mednet.ucla.edu

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Antivir Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT CCR102881 study Related Publications

• A case of chorionepithelioma presenting with subarachnoid haemorrhage.
• A critique of the chronometric evidence for hominid fossils: I. Africa and the Near East 500-50ka.
• A. H. Millard.
• Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
• Appendicectomy in chronic appendicitis.
• Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness.
• C KILLICK Millard.
• Calcium polystyrene sulphonate: an unusual cause of inhalation pneumonia.
• Contact sensitivity to toothpaste.
• DNA interstrand cross-linking by epichlorohydrin.
• Design of surgery premises and employment of nurses.
• Does vaccination help to spread smallpox?
• Early recurrent otitis media, language and central auditory processing in children.
• Effect of size on the function of three day hospitals: the case for the small unit.
• Food service provisions for the cancer patient.
• Fragment-based identification of determinants of conformational and spectroscopic change at the ricin active site.
• GP management of dementia - A consumer perspective.
• Ghrelin-induced food intake and growth hormone secretion are altered in melanocortin 3 and 4 receptor knockout mice.
• Homograft mitral valve replacement in children, 1975 - 1978.
• IN MEMORIAM: Charles Killick Millard, M.D., D.Sc. Edin.
• Measuring the (13)C content of soil-respired CO(2) using a novel open chamber system.
• Multiple pigmented papular basal cell carcinomas: a new pattern of industrial tar induced skin tumours.
• Real-time, frequency-translated holographic visualization of surface acoustic wave interactions with surface-breaking defects.
• Regional survey of femoral neck fractures.
• Relationship between assemblages of mycorrhizal fungi and bacteria on grass roots.
• Shoulder Subluxation in elderly inpatients.
• The end of compulsory vaccination.
• [Case of mixed salivary tumor of the retropharyngeal space.]
• [In Process Citation]
• [Labyrinthine syndromes of cervical origin: their therapy by infiltrations of the vertebral sympathetic nerves and by vertebral neurotomy.]